2023 Annual Meeting | C111 - Multiple Sclerosis Disease-modifying Treatment

Date Monday 04/24/23

Time 03:30 PM - 05:30 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jacqueline Bernard, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants will get a review of indications for using FDA-approved disease-modifying treatments (DMTs) for different phenotypes of multiple sclerosis. AAN guidelines for starting, switching and stopping DMTs will be incorporated into several clinical scenarios. Polling questions will be integrated into the lecture experience in order to engage the audience and encourage vigorous discussion. Treatment decisions related to pregnancy, breastfeeding, and COVID-19 management will be emphasized. Mechanism of action, adverse effects of major groups of DMTs will be discussed as well as recommended surveillance monitoring.

This program is supported in part by educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals.

The Academy was solely responsible, with no influence from the industry supporters, for selection of content, format, presenters, and moderators of this CME program, and the speakers have not been contacted or influenced in any way by the industry supporters with regard to this CME program.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
03:30 PM - 04:15 PM EST	Speaker	Overview of MS Phenotypes, McDonald Criteria, NEDA Concepts, Caveats in Diagnosis, Management, and Strategies Jacqueline Bernard, MD, FAAN
04:15 PM - 05:15 PM EST	Speaker	Updates on Newer DMTs and Emerging Therapies, Special Considerations During COVID. Chris Hollen, MD
05:15 PM - 05:30 PM EST	Discussion	Questions and Answers Jacqueline Bernard, MD, FAAN, Chris Hollen, MD

Faculty Disclosures
Jacqueline Bernard, MD, FAAN	Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care.
Chris Hollen, MD	Dr. Hollen has nothing to disclose.